CoChat

Humanistic and Economic Impact of Subcutaneous Versus Intravenous Administration of Oncology Biologics

Open access

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

Abstract

More oncology biologics are becoming available for subcutaneous (sc.) administration and are expected to provide useful therapeutic options. We evaluated evidence published in the past 5 years to assess the humanistic and economic impact of sc. versus intravenous administration of approved cancer therapies and identify outcomes favoring either administration route. These publications focused predominantly on healthcare resource utilization and economic outcomes, demonstrating resource and cost savings with sc. administration. Patients reported a better health-related quality of life and preference for sc. formulations. Time-and-motion study analyses confirmed the convenience of sc. administration. These findings suggest that future availability of sc. oncology biologics, especially anti-PD-1/PD-ligand 1 antibodies due to their increased utility in various malignancies, may be beneficial for patients, healthcare providers and payers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2217/fon-2019-0368

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Research works printed but not linked: 15

  1. Bacchiarri F , NozzoliC, AntonioliEet al. Safety and efficacy of SC versus IV bortezomib in patients with newly elderly diagnosed multiple myeloma. Haematologica102(Suppl. 3), 167 (2017).
  2. Calvache J , BricenoV. Budget impact analysis of the use of trastuzumab SC in the treatment of HER2 positive in public health institutions of Ecuador. Value Health20, A130 (2017).
  3. Castillo-Fernandez O , CabrejaA, ArauzEet al. Do patients and nurses outside clinical trial prefer SC trastuzumab over conventional IV infusion? Instituto Oncologico Nacional experience. Cancer Res.77(Suppl. 4), P5-11-16 (2017).
  4. Cocquyt VF , Martinez-MenaCL, MartensMTet al. BELIS: safety and tolerability of at home administration of trastuzumab (Herceptin) SC for the treatment of patients with HER2-positive early breast cancer. Cancer Res.77(4; Suppl. 1), P4-21-17 (2017).
  5. Di Rocco A , ScerboG, AnsuinelliMet al. Efficacy, safety and cost analysis of SC vs IV rituximab in patients with diffuse large B-cell lymphoma treated with RCHOP. Haematologica3, 110–111 (2017).
  6. Dumitru D , BensonJ, WishartGet al. Rates of ipsilateral breast tumor recurrence (IBTR) following breast conserving surgery (BCS) and hypofractionated radiotherapy for ductal carcinoma in situ (DCIS). Cancer Res.77(4 Suppl. 1), P1-11-03 (2017).
  7. Gomes G , HoR, RufinoCet al. Budget impact analysis of rituximab IV versus SC from public Brazilian hospital. ISPOR 22nd Annual International Meeting. Boston, MA (2017).
  8. Irwin S , RowntreeC, CoshHet al. Positive benefits of changing from IV rituximab administration to SC administration: a single centre experience. Br. J. Hematol.176(Suppl. 1), 68–69 (2017).
  9. Lopez MA , SamanesMA, TenaIPet al. Switching from IV to SC formulation of trastuzumab: costs and safety. Eur. J. Hosp. Pharm.24(Suppl. 1), A57 (2017).
  10. Martin C , AlcedoJ, AraúzE. Comparative analysis of costs between SC formulation of trastuzumab versus IV formulation from the perspective of the Instituto Oncológico Nacional of Panamá from January to December 2016. Cancer Res.78(Suppl.4), P4-12-13 (2018).
  11. Nierenberger A , GessierF, ForgesFet al. SC trastuzumab versus IV trastuzumab: an impact study. Eur. J. Hosp. Pharm.24, A216 (2017).
  12. Nikolov O , SterjevZ, DimovskiAet al. Cost-minimization analysis of rituximab SC formulation versus IV administration of rituximab for the treatment of non-Hodgkin’s lymphoma in the Republic of Macedonia. Haematologica102(Suppl. 2), 600 (2017).
  13. Petrakova K , MelicharB, BortlicekZet al. Preference of trastuzumab administration route (IV or SC) in patients in the Czech Republic. Cross-sectional study on 429 patients. Cancer Res.77(Suppl.4), P4-21-12 (2017).
  14. Stojanovik A , CvetanovskaL, ChevreskaLet al. Preference of Macedonian NHL patients for SC vs IV administration of rituximab. Leukemia Res.61, S32 (2017).
  15. Tomarchio V , SuranoMA, TafuriMAet al. Management, economic and social impact of sub-cutaneous rituximab administration in lymphoproliferative malignancies. Haematologica102, 298 (2017).

Cited by

See all 69

Metadata

Authors
Anderson, K. C., Landgren, O., Arend, R. C., Chou, J., & Jacobs, I. A.
Affiliations
  • Harvard University (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • University of Alabama at Birmingham (US)
  • Pfizer (United States) (US)
Venue
Future Oncology
Published
2019-08-09
Volume
15
Issue
28
Pages
3267-3281
ISSN
  • 1479-6694 (ISSN-L)
  • 1744-8301
OpenAlex
W2966881177
Cited by
69
References
71
Citations by year
2026: 9 · 2025: 13 · 2024: 15 · 2023: 10 · 2022: 5 · 2021: 10 · 2020: 7
FWCI
1.52
Type
journal article
Language
en
Open access
Locations
  • Future Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • Food and Drug Administration
  • Leukemia and Lymphoma Society
  • Multiple Myeloma Research Foundation
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Keywords
subcutaneous administration, intravenous administration, route of administration, healthcare resource utilization, cost reduction, health-related quality of life, patient preferences, time and motion study, anti-PD-1/PD-L1 antibodies
MeSH terms
Antineoplastic Agents, Biological Products, Cost-Benefit Analysis, Humans, Injections, Subcutaneous, Neoplasms, Prognosis, Administration, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Humanistic and Economic Impact of Subcutaneous Versus Intravenous Administration of Oncology Biologics. https://app.cochat.ai/papers/10.2217/fon-2019-0368
The paper
Anderson, K. C., Landgren, O., Arend, R. C., Chou, J., & Jacobs, I. A. (2019). Humanistic and Economic Impact of Subcutaneous Versus Intravenous Administration of Oncology Biologics. Future Oncology. https://doi.org/10.2217/fon-2019-0368

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.